AKT1 and gastric cancer: For instance, in a mouse model of gastric cancer, PI3K inhibitors targeting the PI3K-AKT-mTOR pathway reduced free fatty acids accumulation and enhanced the efficacy of immune checkpoint (PD-1) inhibitors [42].